메뉴 건너뛰기




Volumn 5, Issue 1, 2009, Pages 301-308

Management of obsessive-compulsive disorder with fluvoxamine extended release

Author keywords

Fluvoxamine; Fluvoxamine extended release; Obsessive compulsive disorder

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOPAMINE RECEPTOR; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; PLASMA PROTEIN; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIGMA OPIATE RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

EID: 70449717878     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (17)

References (62)
  • 1
    • 0030957724 scopus 로고    scopus 로고
    • Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions
    • Goodman WK, Ward H, Kablinger A, et al. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry. 1997;58 Suppl 5:32-49. (Pubitemid 27255355)
    • (1997) Journal of Clinical Psychiatry , vol.58 , Issue.SUPPL. 5 , pp. 32-49
    • Goodman, W.K.1    Ward, H.2    Kablinger, A.3    Murphy, T.4
  • 2
    • 0029160813 scopus 로고
    • Overview of the pharmacokinetics of fluvoxamine
    • van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9.
    • (1995) Clin Pharmacokinet , vol.29 , Issue.SUPPL. 1 , pp. 1-9
    • Van Harten, J.1
  • 3
    • 29244465500 scopus 로고    scopus 로고
    • Fluvoxamine: A selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder
    • DOI 10.1517/14656566.6.15.2727
    • Dell'Osso B, Allen A, Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005;6:2727-2740. (Pubitemid 41824387)
    • (2005) Expert Opinion on Pharmacotherapy , vol.6 , Issue.15 , pp. 2727-2740
    • Dell'Osso, B.1    Allen, A.2    Hollander, E.3
  • 4
    • 85047681662 scopus 로고    scopus 로고
    • The use of escitalopram beyond major depression: Pharmacological aspects, efficacy and tolerability in anxiety disorders
    • DOI 10.1517/17425225.3.5.741
    • Bareggi SR, Mundo E, Dell'Osso B, et al. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007;3:741-753. (Pubitemid 351320641)
    • (2007) Expert Opinion on Drug Metabolism and Toxicology , vol.3 , Issue.5 , pp. 741-753
    • Bareggi, S.R.1    Mundo, E.2    Dell'Osso, B.3    Altamura, A.C.4
  • 6
    • 0026072115 scopus 로고
    • A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder
    • Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:922-927.
    • (1991) Arch Gen Psychiatry , vol.48 , pp. 922-927
    • Leonard, H.L.1    Swedo, S.E.2    Lenane, M.C.3
  • 7
    • 0030799748 scopus 로고    scopus 로고
    • Addition of desipramine to serotonin reuptake inhibitors in treatment- Resistant obsessive-compulsive disorder
    • Barr LC, Goodman WK, Anand A, et al. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997;154:1293-1295. (Pubitemid 27369184)
    • (1997) American Journal of Psychiatry , vol.154 , Issue.9 , pp. 1293-1295
    • Barr, L.C.1    Goodman, W.K.2    Anand, A.3    McDougle, C.J.4    Price, L.H.5
  • 8
    • 0025294010 scopus 로고
    • Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine
    • Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990;47:577-585.
    • (1990) Arch Gen Psychiatry , vol.47 , pp. 577-585
    • Goodman, W.K.1    Price, L.H.2    Delgado, P.L.3
  • 9
    • 0021815938 scopus 로고
    • Tricyclic antidepressants in obsessive-compulsive disorder: Antiobsessional or antidepressant agents? II
    • Mavissakalian M, Turner SM, Michelson L, et al. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessionals or antidepressant agents? II. Am J Psychiatry. 1985;142:572-576. (Pubitemid 15034625)
    • (1985) American Journal of Psychiatry , vol.142 , Issue.5 , pp. 572-576
    • Mavissakalian, M.1    Turner, S.M.2    Michelson, L.3    Jacob, R.4
  • 10
    • 0036109031 scopus 로고    scopus 로고
    • Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder
    • DOI 10.1097/00004714-200206000-00012
    • Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309-317. (Pubitemid 34546847)
    • (2002) Journal of Clinical Psychopharmacology , vol.22 , Issue.3 , pp. 309-317
    • Ackerman, D.L.1    Greenland, S.2
  • 11
    • 0028916905 scopus 로고
    • Efficacy of drug treatment in obsessive-compulsive disorder. a meta-analytic review
    • Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995;166:424-443.
    • (1995) Br J Psychiatry , vol.166 , pp. 424-443
    • Piccinelli, M.1    Pini, S.2    Bellantuono, C.3
  • 12
    • 33744907721 scopus 로고    scopus 로고
    • Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder
    • DOI 10.1016/j.pnpbp.2005.11.005, PII S0278584605003490
    • El Mansari M, Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:362-373. (Pubitemid 43841738)
    • (2006) Progress in Neuro-Psychopharmacology and Biological Psychiatry , vol.30 , Issue.3 , pp. 362-373
    • El Mansari, M.1    Blier, P.2
  • 14
    • 0037383195 scopus 로고    scopus 로고
    • High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography
    • DOI 10.1001/archpsyc.60.4.386
    • Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003;60:386-391. (Pubitemid 36402999)
    • (2003) Archives of General Psychiatry , vol.60 , Issue.4 , pp. 386-391
    • Suhara, T.1    Takano, A.2    Sudo, Y.3    Ichimiya, T.4    Inoue, M.5    Yasuno, F.6    Ikoma, Y.7    Okubo, Y.8
  • 15
  • 16
    • 24944548298 scopus 로고    scopus 로고
    • Effects of dopaminergic and serotonergic manipulation on emotional processing: A pharmacological fMRI study
    • DOI 10.1016/j.neuroimage.2005.05.039, PII S1053811905003599
    • Takahashi H, Yahata N, Koeda M. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage. 2005;27:991-1001. (Pubitemid 41317266)
    • (2005) NeuroImage , vol.27 , Issue.4 , pp. 991-1001
    • Takahashi, H.1    Yahata, N.2    Koeda, M.3    Takano, A.4    Asai, K.5    Suhara, T.6    Okubo, Y.7
  • 17
    • 16544392764 scopus 로고    scopus 로고
    • The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence
    • Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65 Suppl 14:11-17.
    • (2004) J Clin Psychiatry , vol.65 , Issue.SUPPL. 14 , pp. 11-17
    • Denys, D.1    Zohar, J.2    Westenberg, H.G.3
  • 19
    • 34948866293 scopus 로고    scopus 로고
    • Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors
    • Kim CH, Cheon KA, Koo MS, et al. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology. 2007;55:156-162
    • (2007) Neuropsychobiology , vol.55 , pp. 156-162
    • Kim, C.H.1    Cheon, K.A.2    Koo, M.S.3
  • 20
    • 33749852123 scopus 로고    scopus 로고
    • Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals
    • DOI 10.2174/138161206778559614
    • Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006;12: 3857-3876. (Pubitemid 44560699)
    • (2006) Current Pharmaceutical Design , vol.12 , Issue.30 , pp. 3857-3876
    • Hashimoto, K.1    Ishiwata, K.2
  • 21
    • 57349115973 scopus 로고    scopus 로고
    • The sigma enigma: Can sigma receptors provide a novel target for disorders of mood and cognition
    • Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition. J Clin Psychiatry, 2008;69:1673-1674.
    • (2008) J Clin Psychiatry , vol.69 , pp. 1673-1674
    • Stahl, S.M.1
  • 22
    • 0030594575 scopus 로고    scopus 로고
    • Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain
    • DOI 10.1016/0014-2999(96)00254-3
    • Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307:117-119. (Pubitemid 26226293)
    • (1996) European Journal of Pharmacology , vol.307 , Issue.1 , pp. 117-119
    • Narita, N.1    Hashimoto, K.2    Tomitaka, S.-I.3    Minabe, Y.4
  • 25
    • 33748092384 scopus 로고    scopus 로고
    • Animal Models of Obsessive-Compulsive Disorder: Rationale to Understanding Psychobiology and Pharmacology
    • DOI 10.1016/j.psc.2006.02.007, PII S0193953X06000207
    • Korff S, Harvey BH. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am. 2006;29: 371-390. (Pubitemid 44294451)
    • (2006) Psychiatric Clinics of North America , vol.29 , Issue.2 , pp. 371-390
    • Korff, S.1    Harvey, B.H.2
  • 26
    • 0030906968 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of fluvoxamine: Applications to dosage regimen design
    • DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry. 1997;58 Suppl 5:7-14.
    • (1997) J Clin Psychiatry , vol.58 , Issue.SUPPL. 5 , pp. 7-14
    • DeVane, C.L.1    Gill, H.S.2
  • 29
    • 0030610929 scopus 로고    scopus 로고
    • 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder
    • Strauss WL, Layton ME, Hayes CE, et al. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry. 1997;154:516-522.
    • (1997) Am J Psychiatry , vol.154 , pp. 516-522
    • Strauss, W.L.1    Layton, M.E.2    Hayes, C.E.3
  • 30
    • 0020536393 scopus 로고
    • Review of the animal pharmacology and pharmacokinetics of fluvoxamine
    • Claassen V. 1983. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol. 15 Suppl 3:349S-355S.
    • (1983) Br J Clin Pharmacol , vol.15 , Issue.SUPPL. 3
    • Claassen, V.1
  • 31
    • 0031941954 scopus 로고    scopus 로고
    • Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy
    • Strauss WL, Layton ME, Dager SR. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry. 1998;155:380-384.
    • (1998) Am J Psychiatry , vol.155 , pp. 380-384
    • Strauss, W.L.1    Layton, M.E.2    Dager, S.R.3
  • 33
    • 48549093980 scopus 로고    scopus 로고
    • Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update
    • Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206-1227.
    • (2008) Clin Ther , vol.30 , pp. 1206-1227
    • Spina, E.1    Santoro, V.2    D'Arrigo, C.3
  • 34
    • 34249911648 scopus 로고    scopus 로고
    • Fluvoxamine in the treatment of anxiety disorders
    • Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005;1:289-299.
    • (2005) Neuropsychiatr Dis Treat , vol.1 , pp. 289-299
    • Irons, J.1
  • 35
    • 0023472494 scopus 로고
    • Fluvoxamine treatment of obsessive-compulsive disorder
    • Perse TL, Greist JH, Jefferson JW, et al. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry. 1987;144:1543-1548.
    • (1987) Am J Psychiatry , vol.144 , pp. 1543-1548
    • Perse, T.L.1    Greist, J.H.2    Jefferson, J.W.3
  • 37
    • 0000964732 scopus 로고
    • Efficacy of fluvoxamine in obsessive-compulsive disorder: Results of a multicentre, double-blind, placebo-controlled trial
    • Greist JH, Jenike MA, Robinson D, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind, placebo-controlled trial. Eur J Clin Res. 1995;7:195-204.
    • (1995) Eur J Clin Res , vol.7 , pp. 195-204
    • Greist, J.H.1    Jenike, M.A.2    Robinson, D.3
  • 38
    • 0029925952 scopus 로고    scopus 로고
    • Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial
    • Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996;11:21-29. (Pubitemid 26133288)
    • (1996) International Clinical Psychopharmacology , vol.11 , Issue.1 , pp. 21-29
    • Goodman, W.K.1    Kozak, M.J.2    Liebowitz, M.3    White, K.L.4
  • 39
    • 0027527041 scopus 로고
    • Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: One-year followup
    • DOI 10.1016/0165-1781(93)90030-K
    • Cottraux J, Mollard E, Bouvard M, et al. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Res. 1993;49:63-75. (Pubitemid 23329247)
    • (1993) Psychiatry Research , vol.49 , Issue.1 , pp. 63-75
    • Cottraux, J.1    Mollard, E.2    Bouvard, M.3    Marks, I.4
  • 41
    • 0028059773 scopus 로고
    • Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison
    • Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry. 1994;55:301-305.
    • (1994) J Clin Psychiatry , vol.55 , pp. 301-305
    • Freeman, C.P.1    Trimble, M.R.2    Deakin, J.F.3
  • 44
    • 0034010178 scopus 로고    scopus 로고
    • Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder
    • Mundo E, Maina G, Uslenghi C. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2000;15:69-76. (Pubitemid 30142798)
    • (2000) International Clinical Psychopharmacology , vol.15 , Issue.2 , pp. 69-76
    • Mundo, E.1    Maina, G.2    Uslenghi, C.3
  • 45
    • 0034833763 scopus 로고    scopus 로고
    • Fluvoxamine in obsessive-compulsive disorder: Similar efficacy but superior tolerability in comparison with clomipramine
    • DOI 10.1002/hup.317
    • Mundo E, Rouillon F, Figuera ML, et al. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol. 2001;16:461-468. (Pubitemid 32895589)
    • (2001) Human Psychopharmacology , vol.16 , Issue.6 , pp. 461-468
    • Mundo, E.1    Rouillon, F.2    Luisa Figuera, M.3    Stigler, M.4
  • 46
    • 0028905968 scopus 로고
    • Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder
    • Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:11-18.
    • (1995) Int Clin Psychopharmacol , vol.10 , pp. 11-18
    • Stein, D.J.1    Spadaccini, E.2    Hollander, E.3
  • 47
    • 0029889666 scopus 로고    scopus 로고
    • Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)
    • Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRI). Psychopharmacol Bull. 1996;32:167-173. (Pubitemid 26176218)
    • (1996) Psychopharmacology Bulletin , vol.32 , Issue.1 , pp. 167-173
    • Ravizza, L.1    Barzega, G.2    Bellino, S.3    Bogetto, F.4    Maina, G.5
  • 48
  • 49
    • 0036850509 scopus 로고    scopus 로고
    • Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: A PET symptom provocation study
    • Rauch SL, Shin LM, Dougherty DD, et al. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology. 2002;27:782-791.
    • (2002) Neuropsychopharmacology , vol.27 , pp. 782-791
    • Rauch, S.L.1    Shin, L.M.2    Dougherty, D.D.3
  • 50
    • 17644409732 scopus 로고    scopus 로고
    • Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine
    • Ho Pian KL, van Megen HJ, Ramsey NF, et al. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res. 2005;138:89-97.
    • (2005) Psychiatry Res , vol.138 , pp. 89-97
    • Ho Pian, K.L.1    Van Megen, H.J.2    Ramsey, N.F.3
  • 51
    • 0032973086 scopus 로고    scopus 로고
    • Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: A controlled study
    • O'Connor K, Todorov C, Robillard S, et al. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study. Can J Psychiatry. 1999;44:64-71. (Pubitemid 29146429)
    • (1999) Canadian Journal of Psychiatry , vol.44 , Issue.1 , pp. 64-71
    • O'Connor, K.1    Todorov, C.2    Robillard, S.3    Borgeat, F.4    Brault, M.5
  • 54
    • 0036234093 scopus 로고    scopus 로고
    • Sertraline treatment of obsessive-compulsive disorder: Efficacy and tolerability of a rapid titration regimen
    • Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol. 12:181-186.
    • Eur Neuropsychopharmacol , vol.12 , pp. 181-186
    • Bogetto, F.1    Albert, U.2    Maina, G.3
  • 55
    • 1542650167 scopus 로고    scopus 로고
    • Immediate-release versus controlled-release formulations: Pharmacokinetics of newer antidepressants in relation to nausea
    • DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry. 2003;64 Suppl 18:14-19.
    • (2003) J Clin Psychiatry , vol.64 , Issue.SUPPL. 18 , pp. 14-19
    • Devane, C.L.1
  • 56
    • 0028359427 scopus 로고
    • A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder
    • Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559-567.
    • (1994) Arch Gen Psychiatry , vol.51 , pp. 559-567
    • Tollefson, G.D.1    Rampey Jr., A.H.2    Potvin, J.H.3
  • 57
    • 0029759206 scopus 로고    scopus 로고
    • Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder
    • OCD Paroxetine Study Investigators
    • Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry. 1996;169:468-474.
    • (1996) Br J Psychiatry , vol.169 , pp. 468-474
    • Zohar, J.1    Judge, R.2
  • 58
    • 0028911928 scopus 로고
    • Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder
    • Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52: 289-295.
    • (1995) Arch Gen Psychiatry , vol.52 , pp. 289-295
    • Greist, J.1    Chouinard, G.2    Duboff, E.3
  • 59
    • 0031918221 scopus 로고    scopus 로고
    • Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder
    • DOI 10.1016/S0924-977X(97)00048-5, PII S0924977X97000485
    • Koran LM, Pallanti S, Paiva RS, et al. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1998;8:121-126. (Pubitemid 28210338)
    • (1998) European Neuropsychopharmacology , vol.8 , Issue.2 , pp. 121-126
    • Koran, L.M.1    Pallanti, S.2    Paiva, R.S.3    Quercioli, L.4
  • 60
    • 1642539050 scopus 로고    scopus 로고
    • A Double-Blind Placebo-Controlled Study of Controlled Release Fluvoxamine for the Treatment of Generalized Social Anxiety Disorder
    • DOI 10.1097/01.jcp.0000104906.75206.8b
    • Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:49-55. (Pubitemid 38134166)
    • (2004) Journal of Clinical Psychopharmacology , vol.24 , Issue.1 , pp. 49-55
    • Westenberg, H.G.M.1    Stein, D.J.2    Yang, H.3    Li, D.4    Barbato, L.M.5
  • 61
    • 18144368022 scopus 로고    scopus 로고
    • Luvox. Palo Alto: Jazz Pharmaceuticals, Inc.
    • Luvox. 2004. Prescribing Information. Palo Alto: Jazz Pharmaceuticals, Inc.
    • (2004) Prescribing Information


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.